Aileron Therapeutics Inc., a Cambridge biopharmaceutical company, said Monday that it has secured the second tranche in its Series D financing, bringing the total round to $42 million.

Current investors Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis Venture Funds, Roche Venture Fund, and SR One participated in the round, Aileron said in a press release.